1. TransMedics' stock has dropped 47% since October 2024 due to missed earnings and reduced revenue guidance. 2. Despite the valuation drop, high expectations remain for 15% FCF margins and 21% YoY revenue growth. 3. The company has significant debt and needs to navigate profitability and sustained growth to justify valuation.